Panel Recommends Trial of Amgen, Cytokinetics Heart Failure Treatment Continue Without Changes

   By Michael Dabaie

Amgen (AMGN), Cytokinetics Inc. (CYTK) and Servier said Wednesday a study data monitoring committee recommended the Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure continue without changes.

The GALACTIC-HF trial opened to enrollment in late 2016 and is designed to enroll about 8,000 patients in over 35 countries who are either currently hospitalized for a primary reason of heart failure or have had a hospitalization or admission to an emergency room for heart failure within one year prior to screening.

The trial is designed to evaluate whether treatment with omecamtiv mecarbil, when added to standard of care, reduces the risk of heart failure events and cardiovascular death in patients with chronic heart failure with reduced ejection fraction.

Omecamtiv mecarbil is being developed under a collaboration between Amgen and Cytokinetics, with funding and strategic support from Servier.

Cytokinetics shares were up 13% to $9.65 premarket.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

March 20, 2019 09:12 ET (13:12 GMT)

Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2024 to Apr 2024